Further studies should focus on the role of TME in the anti-tumor activity of LRRC15 targeting in sarcomas as well as the potential therapeutic values of strategies combining ABBV-085 with PD-1 or PD-L1 inhibition particularly in UPS, which appears to be one of the STS subtypes that is the most sensitive to such immune checkpoint inhibitors [14]. The gene discussed is LRRC15; the disease is neoplasm.